23948sdkhjf
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

Biogen reports progress with tau-targeting Alzheimer's drug

In a Phase 2 trial, Biogen has reported what it desribes to be the first evidence that a tau-targeting treatment may slow cognitive decline in Alzheimer's disease.
Advertisement

The US biotech company says its experimental drug candidate diranersen, designed to reduce the production of tau in the brain, delivered a clinically meaningful slowing of cognitive decline in patients with early Alzheimer's disease.

The new data come from the open-label extension phase of the study and were presented on Tuesday at the ongoing Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston.

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.078|